Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 19/20 | 0.53 |
| ▸ | ITGB1 | P05556 | 18/20 | 0.53 |
| ▸ | ITGB7 | P26010 | 16/20 | 0.53 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | IL2 | P60568 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL920687 | 0.93 | ITGA4 (0.56) | ITGA4ITGB1ITGB7ALBIL2 | |
| Firategrast SCHEMBL918399 | 0.91 | ITGA4 (0.54) | ITGA4ITGB1ITGB7ALBIL2 | |
| Firategrast SCHEMBL12002530 | 0.91 | ITGA4 (0.54) | ITGA4ITGB1ITGB7ALBIL2 | |
| SCHEMBL919261 | 0.89 | ITGA4 (0.61) | ITGA4ITGB1ITGB7 | |
| Firategrast SCHEMBL1681763 | 0.89 | ITGA4 (0.53) | ITGA4ITGB1ITGB7ALBIL2 | |
| SCHEMBL3195442 | 0.89 | ITGA4 (0.42) | ITGA4ITGB1ITGB7 | |
| SCHEMBL919328 | 0.88 | ITGA4 (0.53) | ITGA4ITGB1ITGB7ALBIL2 | |
| SCHEMBL920778 | 0.86 | ITGA4 (0.47) | ITGA4ITGB1ITGB7 | |
| SCHEMBL27503719 | 0.86 | ITGA4 (0.57) | ITGA4ITGB1ITGB7ALBIL2 | |
| SCHEMBL920085 | 0.86 | ITGA4 (0.57) | ITGA4ITGB1ITGB7ALBIL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289109-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-31 | — | — | US | disclosed |
| US-8501809-B2 | Inhibitors of α4 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20110077299-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | KAWAGUCHI TAKAYUKI | 2011-03-31 | — | — | US | disclosed |
| US-7872151-B2 | asthma, allergic conditions such as rhinitis, inflammatory bowel disease such as ulcerative colitis and Crohn's disease, rheumatoid arthritis, atopic dermatitis, multiple sclerosis; condensing N-(2,6-Difluorobenzoyl)-4-(2,6-dimethoxy-4-formal methylphenyl)-L-phenylalanine ethyl ester with ethanol | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20100113820-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | KAWAGUCHI TAKAYUKI | 2010-05-06 | — | — | US | disclosed |
| US-7671090-B2 | Administering N-(2,6-Dichlorobenzoyl)-4-(2,6-dimethoxy-4-methoxymethylphenyl)-L-phenylalanine ethyl ester for therapy of asthma, inflammatory bowel disease, rheumatoid arthritis and atopic dermatitis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-02 | — | — | US | disclosed |
| US-20090111879-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | KAWAGUCHI TAKAYUKI | 2009-04-30 | — | — | US | disclosed |
| US-7456217-B2 | Inhibitors of alpha4 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-11-25 | — | — | US | disclosed |
| US-7026501-B2 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2006-04-11 | — | — | US | disclosed |
| US-20050282900-A1 | Inhibitors of alpha4 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-12-22 | — | — | US | disclosed |
| EP-1315694-B1 | INHIBITORS OF ALPHA 4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2005-04-06 | — | — | EP | disclosed |
| US-20030176498-A1 | Inhibitors of alpha4mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282900-A1 | Inhibitors of alpha4 mediated cell adhesion | ITGB4, ITGA4, VCAM1 | ITGA4 2/4885ITGB1 24/4885ITGB7 98/4885 |
| US-20130289109-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | ITGB4, ITGA4, VCAM1 | ITGA4 2/4885ITGB1 24/4885ITGB7 98/4885 |
| US-20110077299-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | ITGB4, ITGA4, VCAM1 | ITGA4 2/4885ITGB1 24/4885ITGB7 98/4885 |
| US-20100113820-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | ITGB4, ITGA4, VCAM1 | ITGA4 2/4885ITGB1 24/4885ITGB7 98/4885 |
| US-20030176498-A1 | Inhibitors of alpha4mediated cell adhesion | ITGB4, VCAM1, EPCAM | ITGA4 4/4885ITGB1 9/4885ITGB7 59/4885 |
| US-20090111879-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | ITGB4, ITGA4, VCAM1 | ITGA4 2/4885ITGB1 24/4885ITGB7 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.